Cargando…
Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling
Antitubulin drugs are commonly used for the treatment of numerous cancers. However, either the intrinsic or acquired resistances of patients to these drugs result in the failure of the treatment and high mortality of cancers. Therefore, identifying genes or signalling pathways involved in antitubuli...
Autores principales: | Zhao, Yulei, Yang, Xiaolong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673135/ https://www.ncbi.nlm.nih.gov/pubmed/26183396 |
Ejemplares similares
-
Genetic screening reveals a link between Wnt signaling and antitubulin drugs
por: Khan, A H, et al.
Publicado: (2016) -
Identification of Prolyl isomerase Pin1 as a novel positive regulator of YAP/TAZ in breast cancer cells
por: Khanal, Prem, et al.
Publicado: (2019) -
CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity
por: Zhang, Lin, et al.
Publicado: (2015) -
Combretastatin-Inspired Heterocycles as Antitubulin
Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018) -
CDK7 regulates organ size and tumor growth by safeguarding the Hippo pathway effector Yki/Yap/Taz in the nucleus
por: Cho, Yong Suk, et al.
Publicado: (2020)